Fortrea Welcomes Industry Visionary William Sharbaugh to its Distinguished Board of Directors

Fortrea, a leading global contract research organization (CRO) driving innovation in drug development and patient access, today announced a significant enhancement to its leadership team with the appointment of William Sharbaugh to its Board of Directors, effective September 22, 2025.

This strategic addition underscores Fortrea's commitment to fortifying its governance with seasoned experts who possess deep industry insights and a proven track record of operational excellence.

Mr. Sharbaugh brings to Fortrea a wealth of experience, having held pivotal roles in major healthcare and life sciences organizations, where his leadership consistently drove growth and efficiency.

Prior to joining Fortrea's Board, Mr. Sharbaugh served in executive leadership capacities, most notably as Chief Operating Officer for LabCorp.

His extensive background spans over two decades in critical areas such as global operations, commercial strategy, and financial management within the diagnostics and clinical research sectors. This breadth of experience positions him as an invaluable asset to Fortrea as the company navigates the complex landscape of clinical trials and healthcare solutions.

"We are absolutely thrilled to welcome William Sharbaugh to our Board of Directors," said Tom Pike, Chairman and CEO of Fortrea.

"Bill's profound understanding of the life sciences ecosystem, coupled with his exceptional operational acumen and strategic vision, will be instrumental as we continue to expand our global footprint and deliver innovative solutions to our clients. His insights will undoubtedly contribute significantly to our mission of accelerating the delivery of life-changing therapies to patients worldwide."

Mr.

Sharbaugh's appointment is poised to strengthen Fortrea’s strategic direction, particularly in areas concerning operational efficiency, market expansion, and the integration of cutting-edge technologies. His leadership will help guide Fortrea in its pursuit of becoming the partner of choice for pharmaceutical, biotechnology, and medical device companies seeking to bring new treatments to market faster and more efficiently.

"I am honored and excited to join Fortrea's Board of Directors during such a dynamic period in the company's evolution," commented William Sharbaugh.

"Fortrea is at the forefront of clinical research, and I am deeply impressed by its dedication to scientific excellence and patient-centricity. I look forward to contributing my experience to help Fortrea achieve its ambitious goals and make a lasting impact on global health."

This strategic board appointment reinforces Fortrea's dedication to robust governance and underscores its vision for continued growth and leadership in the global CRO market, ultimately benefiting clients, patients, and stakeholders alike.